{"id":793359,"date":"2024-12-09T08:17:59","date_gmt":"2024-12-09T13:17:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/"},"modified":"2024-12-09T08:17:59","modified_gmt":"2024-12-09T13:17:59","slug":"evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/","title":{"rendered":"Evaxion announces 2025 milestones reflecting continued strong strategy execution"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>With most of Evaxion\u2019s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025<\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong>The 2025 key milestones reflect all parts of Evaxion\u2019s strategy for value realization<\/strong>\n        <\/li>\n<li style=\"text-align:justify\">\n          <strong>Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025<\/strong><\/p>\n<\/li>\n<\/ul>\n<p align=\"justify\">COPENHAGEN, Denmark, December 9, 2024 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, announces its strategic milestones for 2025 after having now achieved almost all the milestones set for 2024.<\/p>\n<p align=\"justify\">The 2025 milestones reflect Evaxion\u2019s high activity level, broad pipeline and strong external interest in potential partnerships around both our AI-Immunology\u2122 platform and pipeline assets. As such, the milestones underscore our continued anticipated strategic progress.<\/p>\n<p align=\"justify\">\u201cWe have been very successful in executing our strategy and plans throughout 2024. This makes us excited and confident looking into 2025, as reflected in the milestones for the year. In essence, our strategy for value creation is unchanged and so is our daily focus on executing this strategy to the benefit of shareholders, patients and employees,\u201d says Christian Kanstrup, CEO of Evaxion.<\/p>\n<p align=\"justify\">Evaxion\u2019s overriding priorities are execution upon our business development strategy, continuation of the ongoing EVX-01 phase 2 trial, the ongoing strengthening of our AI-Immunology\u2122 platform and further advancement of our research activities, including progressing our ERV-based precision vaccine concept towards clinical development. Finally, the focus is, of course, on advancing our existing partnerships, including bringing the MSD collaboration, entered in September 2024, to option exercise.<\/p>\n<p align=\"justify\">All this is reflected in the 2025 milestones as listed below. Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\u00a0<\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Milestones <\/strong>\n          <\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">\n            <strong>Target <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>AI-Immunology\u2122 <\/strong>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Launch of automated lead vaccine candidate design module<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>Business development and partnerships <\/strong>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">At least two new agreements<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">2025<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>EVX-01<\/strong>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">All patients completed EVX-01 dosing<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H1<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>EVX-01 <\/strong>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Supplemental phase 2 biomarker and immunogenicity data<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H1<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>EVX-01 <\/strong>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Two-year phase 2 clinical efficacy readout<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>Precision ERV cancer vaccines <\/strong>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Selection of lead vaccine candidate<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>MSD vaccine collaboration (EVX-B2\/EVX-B3) <\/strong>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">MSD option exercise, up to USD 10 million option exercise fee<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle\">\n            <strong>EVX-V1 <\/strong>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Lead antigens selected for CMV vaccine candidate<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">H2<\/td>\n<\/tr>\n<tr>\n<td style=\"width:168px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;vertical-align: middle\">\n            <strong>Infectious diseases <\/strong>\n          <\/td>\n<td style=\"width:351.27px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-right: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">Two new pipeline candidates<\/td>\n<td style=\"width:81.67px;vertical-align: middle;text-align: left;padding-left: 10.0px;border-top: solid black 1pt;border-left: solid black 1pt;vertical-align: middle\">1 in H1, 1 in H2<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">\n        <strong>Contact information<\/strong>\u00a0<br \/>Evaxion Biotech A\/S<br \/>Mads Kronborg<br \/>Vice President, Investor Relations &amp; Communication<br \/>+45 53 54 82 96<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4NxVnE-rdHk46Ac6VHcz_YR2b6fyIBKkzg95qcK0m3sMVUnRh3OXUKgMg0swnR0pgK6-ezSf-EPC7s4FCe4sF6eAGA6CU42x5zz-LCxiSGA=\" rel=\"nofollow\" target=\"_blank\">mak@evaxion-biotech.com<\/a>\u00a0<\/p>\n<p align=\"justify\">\n        <strong>About EVAXION<\/strong><br \/>\n        <br \/>Evaxion Biotech A\/S is a pioneering TechBio company based upon its AI platform, AI-Immunology\u2122. Evaxion\u2019s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology\u2122, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients\u2019 lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology\u2122 platform and vaccine pipeline, please <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2mt2pnC9IF7rpFXMJpNj_BzNOS4Uefs3vyNlaH8a4QSjpXcDInEqfLq2DcMHVyItrQFjfdFdUk0xQQWnTsVNf3yzSbpgZuV9HjY2QKdyLPw=\" rel=\"nofollow\" target=\"_blank\">visit our website<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-looking statement<\/strong>\u00a0<br \/>This\u00a0announcement contains forward-looking statements\u00a0within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.\u00a0The words\u00a0\u201ctarget,\u201d \u201cbelieve,\u201d \u201cexpect,\u201d \u201chope,\u201d \u201caim,\u201d \u201cintend,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201canticipate,\u201d \u201ccontemplate,\u201d \u201ccontinue,\u201d \u201cestimate,\u201d \u201cplan,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cwill,\u201d \u201ccan have,\u201d \u201clikely,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201ccould,\u201d and other words and terms of similar meaning\u00a0identify forward-looking statements.\u00a0Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares,\u00a0the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our\u00a0business from other significant geopolitical and macro-economic events;\u00a0and other uncertainties affecting our business operations and financial condition.\u00a0For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F\u00a0and other filings\u00a0with the U.S. Securities and Exchange Commission (SEC), which are available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UYg55BmAUTvKRodFv7aAv5zWLN3yQSVmx9GJpv9EDyE9p2_SOZzTjZb2eeCpw7qPqeYdzLTb_diBBg1HWjUrMNEdG-TgtFbIeA8ioBZowMszGVU6yxGZSScWH7bDhQNPzwSNRNPaBfe3Im8ioTJECASQjvaf1e37PRdc_GMqqlFaKfpfnKCLEgPUpb8V7WPw5XcauqCxeMNhU1BJmrJW-P7ECA6O1gvj2sX7CTt8pGQ=\" rel=\"nofollow\" target=\"_blank\"><strong>www.sec.gov<\/strong><\/a>.\u00a0We do not assume any obligation to update any forward-looking statements except as required by law.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTAyNzU0OCM0MDIwMTkyMTIjMjI1MjA4Nw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/MzU4MTdjYzktMjM1My00N2YzLWJkYTktZjZhYTRmMmU4ODQ5LTEyNjM2NDA=\/tiny\/Evaxion-Biotech.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>With most of Evaxion\u2019s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025 The 2025 key milestones reflect all parts of Evaxion\u2019s strategy for value realization Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025 COPENHAGEN, Denmark, December 9, 2024 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, announces its strategic milestones for 2025 after having now achieved almost all the milestones set for 2024. The 2025 milestones reflect Evaxion\u2019s high activity level, broad pipeline and strong external interest in potential partnerships around both our AI-Immunology\u2122 platform and pipeline assets. As such, the milestones underscore our continued anticipated strategic progress. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Evaxion announces 2025 milestones reflecting continued strong strategy execution&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-793359","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaxion announces 2025 milestones reflecting continued strong strategy execution - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion announces 2025 milestones reflecting continued strong strategy execution - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"With most of Evaxion\u2019s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025 The 2025 key milestones reflect all parts of Evaxion\u2019s strategy for value realization Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025 COPENHAGEN, Denmark, December 9, 2024 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, announces its strategic milestones for 2025 after having now achieved almost all the milestones set for 2024. The 2025 milestones reflect Evaxion\u2019s high activity level, broad pipeline and strong external interest in potential partnerships around both our AI-Immunology\u2122 platform and pipeline assets. As such, the milestones underscore our continued anticipated strategic progress. &hellip; Continue reading &quot;Evaxion announces 2025 milestones reflecting continued strong strategy execution&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-09T13:17:59+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTAyNzU0OCM0MDIwMTkyMTIjMjI1MjA4Nw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Evaxion announces 2025 milestones reflecting continued strong strategy execution\",\"datePublished\":\"2024-12-09T13:17:59+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/\"},\"wordCount\":758,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTAyNzU0OCM0MDIwMTkyMTIjMjI1MjA4Nw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/\",\"name\":\"Evaxion announces 2025 milestones reflecting continued strong strategy execution - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTAyNzU0OCM0MDIwMTkyMTIjMjI1MjA4Nw==\",\"datePublished\":\"2024-12-09T13:17:59+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTAyNzU0OCM0MDIwMTkyMTIjMjI1MjA4Nw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTAyNzU0OCM0MDIwMTkyMTIjMjI1MjA4Nw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evaxion announces 2025 milestones reflecting continued strong strategy execution\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion announces 2025 milestones reflecting continued strong strategy execution - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion announces 2025 milestones reflecting continued strong strategy execution - Market Newsdesk","og_description":"With most of Evaxion\u2019s strategic milestones for 2024 now successfully achieved, the company announces milestones for 2025 The 2025 key milestones reflect all parts of Evaxion\u2019s strategy for value realization Evaxion expects to discuss the milestones at an investor event in the first quarter of 2025 COPENHAGEN, Denmark, December 9, 2024 &#8211; Evaxion Biotech A\/S (NASDAQ: EVAX) (\u201cEvaxion\u201d), a clinical-stage TechBio company specializing in developing AI-Immunology\u2122 powered vaccines, announces its strategic milestones for 2025 after having now achieved almost all the milestones set for 2024. The 2025 milestones reflect Evaxion\u2019s high activity level, broad pipeline and strong external interest in potential partnerships around both our AI-Immunology\u2122 platform and pipeline assets. As such, the milestones underscore our continued anticipated strategic progress. &hellip; Continue reading \"Evaxion announces 2025 milestones reflecting continued strong strategy execution\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-09T13:17:59+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTAyNzU0OCM0MDIwMTkyMTIjMjI1MjA4Nw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Evaxion announces 2025 milestones reflecting continued strong strategy execution","datePublished":"2024-12-09T13:17:59+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/"},"wordCount":758,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTAyNzU0OCM0MDIwMTkyMTIjMjI1MjA4Nw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/","name":"Evaxion announces 2025 milestones reflecting continued strong strategy execution - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTAyNzU0OCM0MDIwMTkyMTIjMjI1MjA4Nw==","datePublished":"2024-12-09T13:17:59+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTAyNzU0OCM0MDIwMTkyMTIjMjI1MjA4Nw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTAyNzU0OCM0MDIwMTkyMTIjMjI1MjA4Nw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/evaxion-announces-2025-milestones-reflecting-continued-strong-strategy-execution\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Evaxion announces 2025 milestones reflecting continued strong strategy execution"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793359","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=793359"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/793359\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=793359"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=793359"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=793359"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}